ReproCELL
Kanagawa, JapanWebsite
A pioneer in iPSC technology, providing high-quality cells, reagents, and contract research services for drug discovery and regenerative medicine.
Loading company information...
A pioneer in iPSC technology, providing high-quality cells, reagents, and contract research services for drug discovery and regenerative medicine.
Company context
ReproCELL prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
REPROCELL is a pioneering biotechnology company specializing in induced pluripotent stem cell (iPSC) technology, regenerative medicine, and preclinical drug discovery. Founded in 2003 as a spin-off from Kyoto University and the University of Tokyo, the company has established itself as a global leader in the field, having supported the Nobel Prize-winning research of Professor Shinya Yamanaka. Today, REPROCELL operates across Japan, the United States, and Europe, providing a comprehensive suite of research tools, cell manufacturing services, and therapeutic development pipelines.
REPROCELL is driven by a commitment to improving patient outcomes and human health. The company aims to lead the global regenerative medicine market by providing cutting-edge iPSC technologies and tools that accelerate research and the development of new treatments for intractable diseases and cancer.
Founded
2003
Headquarters
Yokohama, Kanagawa, Japan
Employees
200-500
Industry
Biotechnology
Opportunity to work at the forefront of iPSC and regenerative medicine research
Global collaborative environment with offices in Japan, US, and Europe
High pressure associated with the rigorous regulatory timelines of drug development
Complexity of managing cross-border operations and international regulatory standards
Funding
Publicly traded (JASDAQ)